Successful treatment of persistent and severe SARS‐CoV‐2 infection in a high‐risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies

Seganfredo, Fernanda Braga; Dias, Ana Raquel; Santos, Paulo Ricardo Junges dos; Rebelo, Marta; João, Cristina; Mendes, Dina; Carmo, Eduarda

doi:10.1002/ccr3.6548

Cited by 3 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination mainly works against the spike protein of the COVID-19 virus. As a parenteral drug, this combination gives immediate action in the COVID-19 patients who are hospitalized [57,58] .…”

Section: Market Statusmentioning

confidence: 99%

“…From Phase One to Three, there is not even a single death or serious adverse reactions observed with the REGN-COV2, due to the reason the clinical research is still going on for the same [57,58] .…”

Section: Adverse Effectsmentioning

confidence: 99%

“…In fact, this combination is approved by the EMA in the European countries to treat the COVID-19 patients and has been issued market authorization for the same. By this date, it is evident that in the future, the use of this combination will bring a huge market demand [57,58] .…”

Section: Market Statusmentioning

confidence: 99%

“…Even though the medicine is lower compared to developed countries, still not accessible to the large populations in LMI countries. Therefore, the generic version must be within the limits of accessibility to reach out to the mass population [57,58] .…”

Section: Market Statusmentioning

confidence: 99%

See 3 more Smart Citations

Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics

Kotra¹,

Mallem²,

Kanuri³

et al. 2022

Prog Micobes Mol Biol

View full text Add to dashboard Cite

Chemotherapeutics and biotherapeutics agents have been explored as a potential treatment for COVID-19. This study was aimed to elucidate latest update related to biotherapeutics and chemotherapeutics against COVID-19 and its variants as well as the product specifications and marketing dynamics of its pharmacotherapies. There are several chemotherapeutics that have been studied for the treatment of COVID-19, including Paxlovid (Nirmatrelvir & Ritonavir) fixed dose combination, nirmatrelvir and ritonavir fixed dose combination, Remdesivir (Vekulary/Covifor) fixed dose combination, chloroquine and hydroxychloroquine, molnupiravir, favipiravir, Infliximab (Remsima®) fixed dose combination tocilizumab (Actimera), casirivimab+imdevimab (Ronapreve) fixed dose combination, ivermectin, methylprednisole. These drugs have been repurposed for use in COVID-19 due to their antiviral properties and ability to reduce inflammation. The COVID-19 death cases have significantly reduced because of tested efficacy of advanced biotherapeutics and chemotherapeutics. As for marketing dynamics, the demand for chemotherapeutics for the treatment of COVID-19 has increased significantly since the outbreak of the pandemic. Hence, the prices of anti-viral and monoclonal antibodies in top COVID-19 affected countries is also presented here. Considering the molecular interactions, therapeutic activity, efficacy, and adverse effects, the USFDA and the WHO recommended the aforementioned drugs. The chances of approval seems favouring biotherapeutics as these have the best characteristics among the chemotherapeutics. Overall, this review contributes to the scientific understanding of the COVID-19. This can help to inform future research and development efforts and contribute to the overall advancement of knowledge in the field of medicine.

show abstract

Section: Market Statusmentioning

confidence: 99%

Section: Adverse Effectsmentioning

confidence: 99%

Section: Market Statusmentioning

confidence: 99%

Section: Market Statusmentioning

confidence: 99%

See 2 more Smart Citations

Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics

Kotra¹,

Mallem²,

Kanuri³

et al. 2022

Prog Micobes Mol Biol

View full text Add to dashboard Cite

show abstract

Multiple drugs

2023

Reactions Weekly

View full text Add to dashboard Cite

Effectiveness of nirmatrelvir plus ritonavir treatment for patients with CLL during the Omicron Surge

Tadmor

Alapi

Rokach

2023

Blood

View full text Add to dashboard Cite

Patients with CLL, even in the omicron era and post-vaccination, suffer from persistent covid, higher complications and mortality compared to the general population. In the current study, we evaluated retrospectively the effectiveness of Nirmatrelvir plus ritonavir among 1,080 patients with CLL that were infected with SARS-CoV-2. Nirmatrelvir administration was associated with a reduction in Covid-19-related hospitalization or death by day 35. Specifically, the rate of Covid-19-related hospitalization or death in the treated group compared to the untreated group was 4.8% (14 out of 292) versus 10.2% (75 out of 733). Moreover, we report a 69% relative risk reduction in Covid-19-related hospitalization or death in patients with CLL at the age of 65 years or above. Multivariate analysis indicates that patients older than 65 years, heavily treated patients (>2 prior treatments), patients with recent hospitalizations, IVIG treatment and comorbidity had significant improvement outcomes following treatment with Nirmatrelvir.

show abstract

Successful treatment of persistent and severe SARS‐CoV‐2 infection in a high‐risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies

Cited by 3 publications

References 16 publications

Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics

Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics

Multiple drugs

Effectiveness of nirmatrelvir plus ritonavir treatment for patients with CLL during the Omicron Surge

Contact Info

Product

Resources

About